{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_2",
        "name": "Zinc Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Chelator Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_4",
        "name": "Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_5",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "relativeTo": "First Dose",
        "windowUpper": -7
      },
      {
        "id": "timing_6",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7,
        "relativeTo": "First Dose",
        "windowUpper": -7
      },
      {
        "id": "timing_7",
        "name": "Alcohol Abstinence Prior to Dosing",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 48,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_8",
        "name": "Registration",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_9",
        "name": "First CRU Admission",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -8,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_10",
        "name": "Second CRU Admission",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22.5,
        "relativeTo": "First Dose",
        "windowLower": -0.5,
        "windowUpper": 0.5
      },
      {
        "id": "timing_11",
        "name": "Dose Titration to 30mg",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_12",
        "name": "Pregnancy Testing Frequency",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_13",
        "name": "Pre-dose Fasting",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 10,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_14",
        "name": "Post-dose Meal Delay",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_15",
        "name": "Outpatient Dosing Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 0,
        "relativeTo": "Previous Visit",
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_16",
        "name": "Weekly Safety Monitoring",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_17",
        "name": "Tetrathiomolybdate Washout",
        "type": "Before",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Moderate Transaminase Elevation",
        "instanceType": "Condition",
        "description": "Criteria for moderate liver enzyme elevation requiring dose interruption.",
        "text": "ALT or AST > 3x and <= 5x ULN"
      },
      {
        "id": "cond_2",
        "name": "Severe Transaminase Elevation",
        "instanceType": "Condition",
        "description": "Criteria for severe liver enzyme elevation requiring discontinuation.",
        "text": "ALT or AST > 5x ULN"
      },
      {
        "id": "cond_3",
        "name": "Potential Liver Injury (Hy's Law)",
        "instanceType": "Condition",
        "description": "Criteria for potential drug-induced liver injury requiring dose interruption.",
        "text": "Bilirubin > 2x ULN accompanied by ALT > 3x ULN"
      },
      {
        "id": "cond_4",
        "name": "Anemia",
        "instanceType": "Condition",
        "description": "Criteria for anemia requiring dose reduction.",
        "text": "Hemoglobin < 10 g/dL"
      },
      {
        "id": "cond_5",
        "name": "Thrombocytopenia",
        "instanceType": "Condition",
        "description": "Criteria for low platelets requiring dose reduction.",
        "text": "Platelets < 100,000/mm3"
      },
      {
        "id": "cond_6",
        "name": "Neutropenia",
        "instanceType": "Condition",
        "description": "Criteria for low neutrophils requiring dose reduction.",
        "text": "Neutrophils > 30% decrease from baseline and below reference range"
      },
      {
        "id": "cond_7",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Criteria for neurologic worsening requiring evaluation for dose modification.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_8",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Criteria for psychiatric worsening requiring evaluation for dose modification.",
        "text": "Evidence of clinically significant acute psychiatric worsening"
      },
      {
        "id": "cond_9",
        "name": "SRC Safety Review for Titration",
        "instanceType": "Condition",
        "description": "Condition for dose escalation to 30 mg/day.",
        "text": "The Safety Review Committee (SRC) will review available safety data through Day 23 for each participant before titration to 30 mg/day."
      },
      {
        "id": "cond_10",
        "name": "Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "Adaptive design feature allowing for extension of the outpatient period.",
        "text": "The Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Titration to 30mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "On Day 29, participants will be administered ALXN1840 at 30 mg/day, following a 28-day period at 15 mg/day, pending SRC safety review."
      },
      {
        "id": "trans_2",
        "name": "Dose Interruption for Moderate Transaminase Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT or AST > 3x and <= 5x ULN, temporarily interrupt dosing."
      },
      {
        "id": "trans_3",
        "name": "Discontinuation for Severe Transaminase Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT or AST > 5x ULN, discontinue study intervention."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Anemia or Thrombocytopenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Hemoglobin < 10 g/dL or Platelets < 100,000/mm3, reduce dose to previous dose level or to 15 mg QOD if on 15 mg QD."
      },
      {
        "id": "trans_5",
        "name": "Dose Reduction for Neutropenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Neutrophils > 30% decrease from baseline and below reference range, reduce dose to previous dose level or to 15 mg QOD if on 15 mg QD."
      },
      {
        "id": "trans_6",
        "name": "Dose Interruption for Potential Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2x ULN and ALT > 3x ULN, temporarily interrupt dosing."
      },
      {
        "id": "trans_7",
        "name": "Dose Modification for Neurologic or Psychiatric Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on neurologic or psychiatric worsening."
      },
      {
        "id": "trans_8",
        "name": "Remain on 15mg Dose due to Safety",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Participants may remain on the 15 mg/day dose for the duration of the study if there are safety concerns that prevent up-titration."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participant has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (EOS Visit)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal of Consent",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretion Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participant may be withdrawn at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Discontinuation for Serious Hypersensitivity Reaction",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participants must be considered for discontinuation from study intervention for a serious hypersensitivity reaction."
      },
      {
        "id": "exit_5",
        "name": "Discontinuation for Severe Uncontrolled Infection",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participants must be considered for discontinuation from study intervention for a severe uncontrolled infection."
      },
      {
        "id": "exit_6",
        "name": "Discontinuation for Use of Disallowed Medication",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participants must be considered for discontinuation from study intervention for use of a disallowed medication."
      },
      {
        "id": "exit_7",
        "name": "Discontinuation for Pregnancy",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participants must be considered for discontinuation from study intervention for pregnancy or planned pregnancy."
      },
      {
        "id": "exit_8",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered lost to follow-up if they repeatedly fail to return for scheduled visits and are unable to be contacted by the study site."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Day 23",
        "instanceType": "ScheduledDecisionInstance",
        "description": "SRC reviews safety data through Day 23 to decide if participant can titrate up to 30 mg/day on Day 29.",
        "conditionIds": [
          "cond_9"
        ]
      },
      {
        "id": "dec_2",
        "name": "Ongoing Safety Monitoring Decision",
        "timepointId": "Any Visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "At any point, if safety criteria are met, a decision on dose modification or discontinuation is made based on the corresponding transition rule.",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_8"
        ]
      },
      {
        "id": "dec_3",
        "name": "Outpatient Period Extension Decision",
        "timepointId": "Day 9",
        "instanceType": "ScheduledDecisionInstance",
        "description": "At the discretion of the Investigator, the outpatient period may be extended by up to 14 days.",
        "conditionIds": [
          "cond_10"
        ]
      }
    ],
    "summary": {
      "timingCount": 17,
      "conditionCount": 10,
      "transitionRuleCount": 8,
      "exitCount": 8
    }
  }
}